Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, Institute of Developmental Biology, School of Life Science, Shandong University, Jinan 250100, China.
Trends Cardiovasc Med. 2010 Jul;20(5):172-6. doi: 10.1016/j.tcm.2011.02.002.
Atherosclerosis, a dynamic and progressive vascular disease arising from the combination of endothelial dysfunction and inflammation, is becoming a major killer in the 21st century. Accumulating evidence implicates phosphatidylcholine-specific phospholipase C (PC-PLC) in endothelial dysfunction and several inflammation processes. In addition, in a recent study, we demonstrated that PC-PLC contributed to the progression of atherosclerosis. Considering the important roles of PC-PLC in vascular endothelial cell dysfunction and its proinflammatory properties, we propose that a pharmacological blockade of PC-PLC represents a rational approach to atherosclerosis therapy.
动脉粥样硬化是一种源于内皮功能障碍和炎症的动态进行性血管疾病，正在成为 21 世纪的主要杀手。越来越多的证据表明，磷脂酰胆碱特异性磷脂酶 C（PC-PLC）与内皮功能障碍和几种炎症过程有关。此外，在最近的一项研究中，我们证明了 PC-PLC 有助于动脉粥样硬化的进展。鉴于 PC-PLC 在血管内皮细胞功能障碍和促炎特性中的重要作用，我们提出，用药物阻断 PC-PLC 可能是治疗动脉粥样硬化的一种合理方法。
